RVX-208: Completed Phase II enrollment

On Dec. 23, 2013, Resverlogix said it completed enrollment of 20 patients with pre-diabetes in a double-blind, placebo-controlled, crossover Australian Phase II trial evaluating 100 mg oral RVX-208 tw...